Comparison of recent updates in genetics, immunology, biomarkers, and neuroimaging of primary-progressive and relapsing-remitting multiple sclerosis and the role of ocrelizumab in the management of their refractory cases.
Priyadarshi PrajjwalMohammed Dheyaa Marsool MarsoolShahnaz AsharafPugazhendi InbanSrikanth GadamRukesh YadavNeel VoraVarsha NandwanaAli Dheyaa Marsool MarsoolOmniat Amir HussinPublished in: Health science reports (2023)
Early detection, timely intervention, and the adoption of lifestyle modifications play pivotal roles in enhancing treatment outcomes. Notably, ocrelizumab has demonstrated potential in symptom control and mitigating the rate of disease advancement, further underscoring its clinical significance in the management of MS.